Division of Health Care Finance Landon State Office Building 900 SW Jackson, Suite 900 N Topeka, KS 66612-1220



Phone: 785-296-3981 Fax: 785-296-4813 www.kdheks.gov

Janet Stanek, Secretary

Laura Kelly, Governor

Mental Health Medication Advisory Committee Meeting Agenda, Open Session October 8, 2024 2:30pm-4:30pm

Meeting Location:

This meeting will be held virtually. Please use the information below to join the meeting:

Computer Audio Enabled Zoom Meeting: Link:

https://us02web.zoom.us/j/86476976937?pwd=Rm9GajlRVEJocnZRSExGdWRlVkd1dz09

Required Passcode: 471129 Audio Dial in: +1 312 626 6799 US Toll-free Meeting ID: 864 7697 6937

Members of the public are required to complete a conflict of interest form if they intend to provide public comments to the Board. During the Stakeholder Input/Open Public Comment period, priority will be given to those who submit a COI prior to the meeting. Due to the recent change in meeting location, completed forms will be accepted up until October 1, 2024 (one week before the meeting). Please email the completed form to Anh.Rongish@ks.gov.

COI Form link: https://www.kdhe.ks.gov/DocumentCenter/View/465/Conflict-of-Interest-Form-PDF

Committee Members

DeAnn Jenkins, MD (Chair)
Rebecca Klingler, MD
Elizabeth Gant, APRN, PMHNP-BC
Cord Huston, MD, FAPA

Charles Millhuff, DO Chrissy Glenn, DO William Warnes, MD Jill Reynoldson, PharmD, BCPP

KDHE Staff

Victor Nguyen, PharmD Anh Rongish, PharmD, BCPS Annette Grant, RPh Jennifer Whitworth, CPT Crystal Blackmon, Sr. Administrative Assistant

MCO Staff

Angie Yoo, PharmD, Sunflower State Health Plan
Diane Buckingham, MD, Sunflower State Health Plan
Mark DeMary, PharmD, Aetna Better Health of Kansas
Ahmed Maher, MD, Aetna Better Health of Kansas
Michael Porterfield, PharmD, MBA, United Healthcare Community Plan
Coleman Wheeler, MD, United Healthcare Community Plan

I. Call to Order

A. Announcements

II. Old Business

- A. Review and Approval of July 9, 2024 Meeting Minutes
 - a. Committee Discussion
- B. Follow-up on Prior Authorizations for new beneficiaries
 - a. Committee Discussion

III. New Business

- A. ADHD Medications Safe Use for All Ages
 - Addition of Onyda™ XR.
 - a. Prior Authorization Criteria
 - b. Public Comment
 - c. Committee Discussion
- B. New Medication Advanced Medical Hold Manual Review (AMHMR) Approval Process
 - a. Committee Discussion
- IV. Other Business
 - A. Future Meeting Topics

Committee goals for 2025 MHMAC meeting topics

- a. Committee Discussion
- B. Upcoming MHMAC meeting

Committee Preference for virtual or in-person for the upcoming meeting

- a. Committee Discussion
- V. Stakeholder Input/Open Public Comment
- VI. Adjourn